Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial

The Lancet Respiratory Medicine

Volumn 6, Issue 10, 2018, Pages 759-770

  Visca, Dina ^a,b   Mori, Letizia ^a   Tsipouri, Vicky ^a   Fleming, Sharon ^a   Firouzi, Ashi ^a   Bonini, Matteo ^a   Pavitt, Matthew J ^a   Alfieri, Veronica ^a,e   Canu, Sara ^a,f   Bonifazi, Martina ^a,g   Boccabella, Cristina ^a,h   De Lauretis, Angelo ^a,i   Stock, Carmel J W ^a,c   Saunders, Peter ^a,c   Montgomery, Andrew ^a   Hogben, Charlotte ^a   Stockford, Anna ^j   Pittet, Margaux ^j   Brown, Jo ^k   Chua, Felix ^a   George, Peter M ^a   Molyneaux, Philip L ^a,c   Margaritopoulos, Georgios A ^a   Kokosi, Maria ^a   Kouranos, Vasileios ^a   Russell, Anne Marie ^a,d   Birring, Surinder S ^l   Chetta, Alfredo ^e   Maher, Toby M ^a,c   Cullinan, Paul ^d   Hopkinson, Nicholas S ^a   Banya, Winston ^a,d   Whitty, Jennifer A ^m   Adamali, Huzaifa ^j   Spencer, Lisa G ^k   Farquhar, Morag ⁿ   Sestini, Piersante ^o   Wells, Athol U ^a,c   Renzoni, Elisabetta A ^a,c   more..

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b IRCCS   (Italy)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^e UNIVERSITY OF PARMA   (Italy)

^f UNIVERSITY OF SASSARI   (Italy)

^g UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^h CATHOLIC UNIVERSITY   (Italy)

ⁱ Ospedale Salvini   (Italy)

^j SOUTHMEAD HOSPITAL   (United Kingdom)

^k UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^l KING'S COLLEGE LONDON   (United Kingdom)

^m UNIVERSITY OF EAST ANGLIA   (United Kingdom)

ⁿ UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^o UNIVERSITY OF SIENA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AGE; AGED; AMBULATORY CARE; ARTERIAL OXYGEN SATURATION; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEATH; DISEASE ACTIVITY; DISEASE ASSOCIATION; DYSPNEA; EXERTIONAL HYPOXIA; FEMALE; FOLLOW UP; HUMAN; HYPOXIA; INTENTION TO TREAT ANALYSIS; INTERSTITIAL LUNG DISEASE; KING BRIEF INTERSTITIAL LUNG DISEASE QUESTIONNAIRE; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; OXYGEN DESATURATION; OXYGEN THERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE ASSESSMENT; SELF REPORT; SEMI STRUCTURED INTERVIEW; SIX MINUTE WALK TEST; TREATMENT DURATION; TREATMENT OUTCOME; UNITED KINGDOM; UPPER RESPIRATORY TRACT INFECTION; CLINICAL TRIAL; MIDDLE AGED; PROCEDURES; PSYCHOLOGY; STATISTICAL MODEL;

OXYGEN;

AGED; CROSS-OVER STUDIES; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; LINEAR MODELS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; OXYGEN; OXYGEN INHALATION THERAPY; PROSPECTIVE STUDIES; PULMONARY FIBROSIS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 85054779154     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(18)30289-3     Document Type: Article

References (43)

1. Raghu, G, Collard, HR, Egan, JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183 (2011), 788–824.
2. King, TE Jr, Bradford, WZ, Castro-Bernardini, S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370 (2014), 2083–2092.
3. Richeldi, L, du Bois, RM, Raghu, G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370 (2014), 2071–2082.
4. Nishiyama, O, Taniguchi, H, Kondoh, Y, et al. Health-related quality of life in patients with idiopathic pulmonary fibrosis. What is the main contributing factor?. Respir Med 99 (2005), 408–414.
5. Swigris, JJ, Gould, MK, Wilson, SR, Health-related quality of life among patients with idiopathic pulmonary fibrosis. Chest 127 (2005), 284–294.
6. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med 93 (1980), 391–398.
7. Albert, RK, Au, DH, Blackford, AL, et al. A randomized trial of long-term oxygen for COPD with moderate desaturation. N Engl J Med 375 (2016), 1617–1627.
8. Du Plessis, JP, Fernandes, S, Jamal, R, et al. Exertional hypoxemia is more severe in fibrotic interstitial lung disease than in COPD. Respirology 23 (2018), 392–398.
9. Hardinge, M, Suntharalingam, J, Wilkinson, T, Guideline update: the British Thoracic Society Guidelines on home oxygen use in adults. Thorax 70 (2015), 589–591.
10. Jo, HE, Prasad, JD, Troy, LK, et al. Diagnosis and management of idiopathic pulmonary fibrosis: Thoracic Society of Australia and New Zealand and Lung Foundation Australia position statements summary. Med J Aust 208 (2018), 82–88.
11. Bell, EC, Cox, NS, Goh, N, et al. Oxygen therapy for interstitial lung disease: a systematic review. Eur Respir Rev, 26, 2017, 160080.
12. Sharp, C, Adamali, H, Millar, AB, Ambulatory and short-burst oxygen for interstitial lung disease. Cochrane Database Syst Rev, 7, 2016 CD011716.
13. Schaeffer, MR, Ryerson, CJ, Ramsook, AH, et al. Effects of hyperoxia on dyspnoea and exercise endurance in fibrotic interstitial lung disease. Eur Respir J, 49, 2017, 1602494.
14. Dowman, LM, McDonald, CF, Bozinovski, S, et al. Greater endurance capacity and improved dyspnoea with acute oxygen supplementation in idiopathic pulmonary fibrosis patients without resting hypoxaemia. Respirology 22 (2017), 957–964.
15. Graney, BA, Wamboldt, FS, Baird, S, et al. Looking ahead and behind at supplemental oxygen: a qualitative study of patients with pulmonary fibrosis. Heart Lung 46 (2017), 387–393.
16. Khor, YH, Goh, NSL, McDonald, CF, Holland, AE, Oxygen therapy for interstitial lung disease. A mismatch between patient expectations and experiences. Ann Am Thorac Soc 14 (2017), 888–895.
17. Ryerson, CJ, Camp, PG, Eves, ND, et al. High oxygen delivery to preserve exercise capacity in patients with idiopathic pulmonary fibrosis treated with nintedanib. Methodology of the HOPE-IPF study. Ann Am Thorac Soc 13 (2016), 1640–1647.
18. Visca, D, Tsipouri, V, Mori, L, et al. Ambulatory oxygen in fibrotic lung disease (AmbOx): study protocol for a randomised controlled trial. Trials, 18, 2017, 201.
19. Leach, RM, Davidson, AC, Chinn, S, Twort, CH, Cameron, IR, Bateman, NT, Portable liquid oxygen and exercise ability in severe respiratory disability. Thorax 47 (1992), 781–789.
20. Holland, AE, Spruit, MA, Troosters, T, et al. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J 44 (2014), 1428–1446.
21. Wells, AU, Desai, SR, Rubens, MB, et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med 167 (2003), 962–969.
22. Borg, GA, Psychophysical bases of perceived exertion. Med Sci Sports Exerc 14 (1982), 377–381.
23. Ritchie, J, Spencer, L, Qualitative data analysis for applied policy research. Bryman, A, Burgess, RG, (eds.) Analyzing qualitative data, 1994, Routledge, London, 173–194.
24. Patel, AS, Siegert, RJ, Brignall, K, et al. The development and validation of the King's Brief Interstitial Lung Disease (K-BILD) health status questionnaire. Thorax 67 (2012), 804–810.
25. Eakin, EG, Resnikoff, PM, Prewitt, LM, Ries, AL, Kaplan, RM, Validation of a new dyspnea measure: the UCSD Shortness of Breath Questionnaire. University of California, San Diego. Chest 113 (1998), 619–624.
26. Jones, PW, Quirk, FH, Baveystock, CM, The St George's Respiratory Questionnaire. Respir Med 85:suppl B (1991), 25–31.
27. Zigmond, AS, Snaith, RP, The hospital anxiety and depression scale. Acta Psychiatr Scand 67 (1983), 361–370.
28. Bjelland, I, Dahl, AA, Haug, TT, Neckelmann, D, The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res 52 (2002), 69–77.
29. Mi, E, Mi, E, Ewing, G, et al. Associations between the psychological health of patients and carers in advanced COPD. Int J Chron Obstruct Pulmon Dis 12 (2017), 2813–2821.
30. Patel, AS, Siegert, RJ, Keir, GJ, et al. The minimal important difference of the King's Brief Interstitial Lung Disease Questionnaire (K-BILD) and forced vital capacity in interstitial lung disease. Respir Med 107 (2013), 1438–1443.
31. Senn, S, Cross-over trials in clinical research. 2nd edn., 2002, Wiley, Chichester.
32. Jones, BE, Kenwood, MG, Design and Analysis of Cross-Over Trials. 3rd edn., 2014, Chapman and Hall, CRC Press, New York.
33. Koch, GG, The use of non-parametric methods in the statistical analysis of the two-period change-over design. Biometrics 28 (1972), 577–584.
34. Barker, RE, Nolan, CM, Delogu, V, et al. The King's Brief Interstitial Lung Disease Questionnaire: response to pulmonary rehabilitation and minimal important difference. Am J Respir Crit Care Med, 195, 2017, A2849.
35. Manini, TM, Everhart, JE, Patel, KV, et al. Daily activity energy expenditure and mortality among older adults. JAMA 296 (2006), 171–179.
36. Horita, N, Miyazawa, N, Morita, S, et al. Small, moderate, and large changes, and the minimum clinically important difference in the University of California, San Diego Shortness of Breath Questionnaire. COPD 11 (2014), 26–32.
37. Arnold, E, Bruton, A, Donovan-Hall, M, Fenwick, A, Dibb, B, Walker, E, Ambulatory oxygen: why do COPD patients not use their portable systems as prescribed? A qualitative study. BMC Pulm Med, 11, 2011, 9.
38. Redelmeier, DA, Bayoumi, AM, Goldstein, RS, Guyatt, GH, Interpreting small differences in functional status: the Six Minute Walk test in chronic lung disease patients. Am J Respir Crit Care Med 155 (1997), 1278–1282.
39. Carpagnano, GE, Kharitonov, SA, Foschino-Barbaro, MP, Resta, O, Gramiccioni, E, Barnes, PJ, Supplementary oxygen in healthy subjects and those with COPD increases oxidative stress and airway inflammation. Thorax 59 (2004), 1016–1019.
40. Wang, Y, Chai, Y, He, X, et al. Intermittent hypoxia simulating obstructive sleep apnea causes pulmonary inflammation and activates the Nrf2/HO-1 pathway. Exp Ther Med 14 (2017), 3463–3470.
41. Prabhakar, NR, Semenza, GL, Adaptive and maladaptive cardiorespiratory responses to continuous and intermittent hypoxia mediated by hypoxia-inducible factors 1 and 2. Physiol Rev 92 (2012), 967–1003.
42. Abernethy, AP, McDonald, CF, Frith, PA, et al. Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial. Lancet 376 (2010), 784–793.
43. Liss, HP, Grant, BJ, The effect of nasal flow on breathlessness in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 137 (1988), 1285–1288.